Treatment of patients with metastatic urothelial cancer „unfit“ for cisplatin treatment
03/2019
MUDr. Kristýna Divišová1; MUDr. Jana Katolická, Ph.D.2; MUDr. Milan Kohoutek1
1 Onkologické oddělení, Krajská nemocnice Tomáše Bati, Zlín
2 Onkologicko-chirurgické oddělení, FN u svaté Anny, Brno
SUMMARY
Cisplatin-based chemotherapy is the standard first-line treatment in advanced urothelial cancers. However, more than 50 % of patients are not eligible for cisplatin. Urothelial cancer patients are of higher median age and often present with organ impairment and comorbidities. In frail patients, recommended treatment options include carboplatin or gemcitabine monotherapy, or GCa or imunotherapy if possible.
Key words
metastatic urothelial cancer, unfit to cisplatine, carboplatine, imunotherapy,
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...